510(k) · Radiology

EFAI ChestSuite XR Pleural Effusion Assessment System

by Ever Fortune.AI Co., Ltd.

EFAI ChestSuite XR Pleural Effusion Assessment System is an AI-enabled medical device from Ever Fortune.AI Co., Ltd. that the U.S. FDA cleared through 510(k) K222076 on September 8, 2022. Its lead review panel is Radiology and its primary product code is QFM (Radiological Computer-Assisted Prioritization Software For Lesions).

See also FDA-cleared AI radiology devices in 2022, all FDA AI clearances in 2022, top radiology AI devices.

Key facts

Submission numberK222076
Pathway510(k)
Date of final decision
Company (FDA list)Ever Fortune.AI Co., Ltd.
Lead review panelRadiology
Primary product codeQFM — Radiological Computer-Assisted Prioritization Software For Lesions
Applicant (openFDA)Ever Fortune.Ai, Co., Ltd.
Applicant locationTaichung City, TW
Device classClass 2
Regulation number21 CFR 892.2080
Decision codeSESE
Submission typeTraditional

Source: FDA AI-Enabled Medical Devices list and openFDA.

What this means

A 510(k) is a premarket submission showing the device is substantially equivalent to a legally marketed predicate device. A cleared 510(k) means FDA agreed with that equivalence. EFAI ChestSuite XR Pleural Effusion Assessment System went through this pathway (K222076).

openFDA lists it as a Class 2 device under 21 CFR 892.2080. Class II devices are moderate risk and are subject to general and special controls.

Product code QFM covers 40 devices on the FDA AI list. By decision date, this device is #19 of 40 under that code. Ever Fortune.AI Co., Ltd. has 10 AI-enabled devices on the list, and the Radiology panel accounts for 1,230 in total.

Being on this list doesn't describe how well the device works clinically. Check the FDA record for its indications for use.

Similar devices (product code QFM)

More from Ever Fortune.AI Co., Ltd.